Table 5.

Results of sensitivity analyses

	All hematological malignancies				Lymphoid malignancies				Myeloid malignancies and AL
	#	ERR/100 mGy	95% CI		#	ERR/100 mGy	95% CI		#	ERR/100 mGy	95% CI
Main results	790	1.96	1.10	3.12	578	2.01	1.02	3.42	203	2.02	0.47	4.77
ABM doses
Doses lagged by 1 year	790	1.99	1.13	3.16	578	2.04	1.05	3.47	203	2.07	0.54	4.80
Doses lagged by 5 years	790	1.06	0.45	1.82	578	1.25	0.53	2.20	203	0.60	−0.43	2.20
Use of median of dose realizations instead of mean	790	2.08	1.09	3.42	578	2.13	0.99	3.75	203	2.17	0.36	5.35
Analyses restricted to individuals with cumulative doses up to:
99th percentile	777	3.17	1.90	4.91	567	3.02	1.59	5.09	201	3.81	1.43	8.20
98th percentile	761	3.54	2.08	5.55	554	3.27	1.66	5.63	198	4.43	1.67	9.62
95th percentile	710	2.80	1.27	4.94	520	2.79	1.02	5.41	181	2.88	0.34	7.75
Exclusions
5 years from first CT	524	2.36	1.21	4.05	381	2.54	1.19	4.66	139	1.74	0.05	5.25
10 years from first CT	261	2.67	1.02	5.69	185	3.12	1.13	7.08	72	1.28	-0.62	8.11
Individuals born before the start of cancer registration	490	1.54	0.68	2.80	365	1.59	0.60	3.14	119	1.84	0.20	5.29
Hospitals with low reporting consistency	603	1.93	0.97	3.29	440	2.17	1.00	3.93	158	1.49	0.00	4.31
Follow-up 2 years after country-specific maximum age at exposure	491	1.27	0.49	2.39	356	1.26	0.39	2.63	128	1.61	0.11	6.61
Individuals with no vital status	739	1.73	0.89	2.97	541	1.91	0.91	3.35	189	1.39	0.03	3.85
United Kingdom—main results		NA			276	2.77	1.12	5.55		NA
Excluding individuals who underwent transplant		NA			256	2.57	0.97	5.31		NA

#, number of hematological malignancies cases; NA, not applicable.